Skip to menu Skip to content Skip to footer
Professor David Ascher
Professor

David Ascher

Email: 
Phone: 
+61 7 336 53991

Overview

Background

Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.

David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).

Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.

David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.

In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.

He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.

Availability

Professor David Ascher is:
Available for supervision
Media expert

Research impacts

We have successfully translated our computational tools into the clinic and industry, including:

  • Clinical detection of drug resistance from whole-genome sequencing of pathogens, including Tuburculosis and Leprosy
  • Genetic counselling for rare diseases and cancers with Addenbrooke's Hospital and Brazilian Ministry of Health
  • Patient stratification within clinical trials
  • Implementation within industry drug and biologics development programs

The tools we have developed have also been widely adopted within existing academic programs including:

  • Integration of intermolecular interaction calculations using our tool Arpeggio in the PDBe, the European resource for the collection, organisation and dissemination of data on biological macromolecular structures.
  • Integration of our missense tolerance scores within the widely used VEP tool for variant characterisation.
  • Implementation of our resistance prediction tools within the London School of Hygiene & Tropical Medicine's TB-Profiler tool.

Works

Search Professor David Ascher’s works on UQ eSpace

177 works between 2008 and 2024

161 - 177 of 177 works

2014

Journal Article

Anti-Aβ antibody target engagement: a response to Siemers et al.

Watt, Andrew D, Crespi, Gabriela A N, Down, Russell A, Ascher, David B, Gunn, Adam, Perez, Keyla A, McLean, Catriona A, Villemagne, Victor L, Parker, Michael W, Barnham, Kevin J and Miles, Luke A (2014). Anti-Aβ antibody target engagement: a response to Siemers et al.. Acta Neuropathologica, 128 (4), 611-4. doi: 10.1007/s00401-014-1333-8

Anti-Aβ antibody target engagement: a response to Siemers et al.

2014

Journal Article

DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach

Pires, Douglas E. V., Ascher, David B. and Blundell, Tom L. (2014). DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Research, 42 (Web Server issue), W314-W319. doi: 10.1093/nar/gku411

DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach

2014

Journal Article

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Watt, Andrew D, Crespi, Gabriela A N, Down, Russell A, Ascher, David B, Gunn, Adam, Perez, Keyla A, McLean, Catriona A, Villemagne, Victor L, Parker, Michael W, Barnham, Kevin J and Miles, Luke A (2014). Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?. Acta Neuropathologica, 127 (6), 803-810. doi: 10.1007/s00401-014-1290-2

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

2014

Journal Article

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

Ascher, David B., Wielens, Jerome, Nero, Tracy L., Doughty, Larissa, Morton, Craig J. and Parker, Michael W. (2014). Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Scientific Reports, 4 (1) 4765. doi: 10.1038/srep04765

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

2014

Journal Article

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β

Crespi, Gabriela A N, Ascher, David B, Parker, Michael W and Miles, Luke A (2014). Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β. Acta Crystallographica. Section F, Structural Biology Communications, 70 (Pt 3), 374-7. doi: 10.1107/S2053230X14001642

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β

2014

Journal Article

Structural studies of Streptococcus pyogenes streptolysin O provide insights into the early steps of membrane penetration

Feil, Susanne C, Ascher, David B, Kuiper, Michael J, Tweten, Rodney K and Parker, Michael W (2014). Structural studies of Streptococcus pyogenes streptolysin O provide insights into the early steps of membrane penetration. Journal of Molecular Biology, 426 (4), 785-792. doi: 10.1016/j.jmb.2013.11.020

Structural studies of Streptococcus pyogenes streptolysin O provide insights into the early steps of membrane penetration

2014

Journal Article

mCSM: predicting the effects of mutations in proteins using graph-based signatures

Pires, Douglas E V, Ascher, David B and Blundell, Tom L (2014). mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics, 30 (3), 335-42. doi: 10.1093/bioinformatics/btt691

mCSM: predicting the effects of mutations in proteins using graph-based signatures

2013

Journal Article

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

Kaminskas, Lisa M., Ascher, David B., McLeod, Victoria M., Herold, Marco J., Le, Caroline P., Sloan, Erica K. and Porter, Christopher J. H. (2013). PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. Journal of Controlled Release, 168 (2), 200-208. doi: 10.1016/j.jconrel.2013.03.006

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

2013

Journal Article

Structure of the N-terminal domain of human thioredoxin-interacting protein

Polekhina, Galina, Ascher, David Benjamin, Kok, Shie Foong, Beckham, Simone, Wilce, Matthew and Waltham, Mark (2013). Structure of the N-terminal domain of human thioredoxin-interacting protein. Acta Crystallographica. Section D: Structural Biology, 69 (Pt 3), 333-344. doi: 10.1107/S0907444912047099

Structure of the N-terminal domain of human thioredoxin-interacting protein

2012

Journal Article

Structural approaches to probing metal interaction with proteins

Parker, Lorien J, Ascher, David B, Gao, Chen, Miles, Luke A, Harris, Hugh H and Parker, Michael W (2012). Structural approaches to probing metal interaction with proteins. Journal of Inorganic Biochemistry, 115, 138-47. doi: 10.1016/j.jinorgbio.2012.02.015

Structural approaches to probing metal interaction with proteins

2012

Journal Article

Crystallization and preliminary X-ray diffraction analysis of human endoplasmic reticulum aminopeptidase 2

Ascher, David B, Polekhina, Galina and Parker, Michael W (2012). Crystallization and preliminary X-ray diffraction analysis of human endoplasmic reticulum aminopeptidase 2. Acta Crystallographica. Section F: Structural Biology Communications, 68 (Pt 4), 468-71. doi: 10.1107/S1744309112006963

Crystallization and preliminary X-ray diffraction analysis of human endoplasmic reticulum aminopeptidase 2

2011

Journal Article

Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation

Parker, Lorien J., Italiano, Louis C., Morton, Craig J., Hancock, Nancy C., Ascher, David B., Aitken, Jade B., Harris, Hugh H., Campomanes, Pablo, Rothlisberger, Ursula, De Luca, Anastasia, Lo Bello, Mario, Ang, Wee Han, Dyson, Paul J. and Parker, Michael W. (2011). Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation. Chemistry-A European Journal, 17 (28), 7806-7816. doi: 10.1002/chem.201100586

Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation

2011

Journal Article

Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein

Polekhina, Galina, Ascher, David Benjamin, Kok, Shie Foong and Waltham, Mark (2011). Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein. Acta Crystallographica. Section F: Structural Biology Communications, 67 (Pt 5), 613-617. doi: 10.1107/S1744309111010347

Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein

2011

Journal Article

Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain

Ascher, David B, Cromer, Brett A, Morton, Craig J, Volitakis, Irene, Cherny, Robert A, Albiston, Anthony L, Chai, Siew Yeen and Parker, Michael W (2011). Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain. Biochemistry, 50 (13), 2611-22. doi: 10.1021/bi101893w

Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain

2008

Journal Article

Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase

Chai, Siew Yeen, Yeatman, Holly R., Parker, Michael W., Ascher, David B., Thompson, Philip E., Mulvey, Hayley T. and Albiston, Anthony L. (2008). Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neuroscience, 9 Suppl 2 (Supplement 2) S14. doi: 10.1186/1471-2202-9-S2-S14

Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase

2008

Journal Article

Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase

Albiston, Anthony L, Morton, Craig J, Ng, Hooi Ling, Pham, Vi, Yeatman, Holly R, Ye, Siying, Fernando, Ruani N, De Bundel, Dimitri, Ascher, David B, Mendelsohn, Frederick A O, Parker, Michael W and Chai, Siew Yeen (2008). Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB Journal, 22 (12), 4209-17. doi: 10.1096/fj.08-112227

Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase

2008

Journal Article

Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase

Ye, Siying, Chai, Siew Yeen, Lew, Rebecca A, Ascher, David B, Morton, Craig J, Parker, Michael W and Albiston, Anthony L (2008). Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase. Biochemistry and Cell Biology, 86 (3), 251-61. doi: 10.1139/o08-037

Identification of modulating residues defining the catalytic cleft of insulin-regulated aminopeptidase

Funding

Current funding

  • 2023 - 2027
    Improving genetic diagnosis of autoimmune and autoinflammatory disease through an integrated multi-omics approach (MRFF 2022 GHFM - administered by ANU)
    The Australian National University
    Open grant

Supervision

Availability

Professor David Ascher is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Developing structure-based deep learning methods to predict mutation effects on proteins

    Principal Advisor

  • Doctor Philosophy

    Computer-aided drug design: predicting and mitigating drug toxicity

    Principal Advisor

    Other advisors: Dr Stephanie Portelli

  • Doctor Philosophy

    Exploring Cardiotoxicity Risk Factors

    Principal Advisor

    Other advisors: Dr Thanh-Binh Nguyen

  • Doctor Philosophy

    Post-transcriptional gene regulation: towards a better understanding of pathogenesis and medical applications

    Principal Advisor

  • Doctor Philosophy

    Computational approaches to engineer and modulate G protein-coupled receptors

    Principal Advisor

  • Doctor Philosophy

    Personalising treatments for genetic diseases

    Principal Advisor

    Other advisors: Dr Stephanie Portelli

  • Doctor Philosophy

    Deep Learning Algorithms for Polygenic Genotype-Phenotype Predictions and the development of genetics computation tools

    Principal Advisor

  • Doctor Philosophy

    Towards the accurate functional characterisation of protein coding mutations

    Principal Advisor

    Other advisors: Dr Stephanie Portelli, Dr Thanh-Binh Nguyen

  • Doctor Philosophy

    Improving rational antibody design using machine learning

    Principal Advisor

  • Doctor Philosophy

    Machine Learning for Protein Dynamics: Predicting Post-Translational Modifications and Mutation Effects

    Principal Advisor

  • Doctor Philosophy

    Using Deep Learning in Cell & Gene Therapy

    Principal Advisor

    Other advisors: Dr Thanh-Binh Nguyen, Dr Stephanie Portelli

  • Doctor Philosophy

    Protein structure guided precision medicine

    Principal Advisor

    Other advisors: Professor Phil Hugenholtz, Dr Stephanie Portelli

  • Doctor Philosophy

    Rational protein engineering and inhibition

    Principal Advisor

  • Doctor Philosophy

    Allosteric modulation of synaptic proteins by endogenous and modified sterols

    Associate Advisor

    Other advisors: Dr Evelyne Deplazes, Professor Megan O'Mara

  • Doctor Philosophy

    Breaking the chain of inflammation through targetting NLR proteins

    Associate Advisor

    Other advisors: Professor Avril Robertson

  • Doctor Philosophy

    Therapeutic Resolution of Inflammation in the Central Nervous System for Neuroprotection in Parkinson's Disease

    Associate Advisor

    Other advisors: Professor Avril Robertson

  • Doctor Philosophy

    Use of structural phylogeny and reconciliation in molecular phylogenetics

    Associate Advisor

    Other advisors: Dr Kate Bowerman, Professor Phil Hugenholtz

  • Doctor Philosophy

    Computational design of targeted lipid technologies

    Associate Advisor

    Other advisors: Professor Megan O'Mara

Media

Enquiries

Contact Professor David Ascher directly for media enquiries about their areas of expertise.

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au